{
    "clinical_study": {
        "@rank": "147965", 
        "arm_group": [
            {
                "arm_group_label": "PH-797804", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single 24 mg dose in the fed state"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single 400 mg dose in the fed state"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single placebo dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of PH-797804 following dosing of a 24\n      mg oral tablet on the QTc interval"
        }, 
        "brief_title": "A Study to Investigate the Effect of PH-797804 on QTc Interval", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects and/or healthy female subjects of non-child bearing potential\n             between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically\n             relevant abnormalities identified by a detailed medical history, full physical\n             examination, including blood pressure and pulse rate measurements, 12-lead ECG and\n             clinical laboratory tests.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110\n             lbs).\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing).\n\n          -  A positive urine drug screen.\n\n          -  History of regular alcohol consumption exceeding 14 drinks/week for males."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862887", 
            "org_study_id": "A6631035"
        }, 
        "intervention": [
            {
                "arm_group_label": "PH-797804", 
                "description": "Tablet, 24 mg, single dose", 
                "intervention_name": "PH-797804", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "description": "Tablet, 400 mg, single dose", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Tablet, PH-797804 matched placebo, single dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 14, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6631035&StudyName=A%20Study%20to%20Investigate%20the%20Effect%20of%20PH-797804%20on%20QTc%20Interval"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Randomized, Placebo-And Positive-Controlled Crossover Study To Determine The Effect Of A Single-Dose Of PH-797804 On QTc Interval In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "QT interval corrected for heart rate using Fredericias correction", 
            "measure": "QTcF Interval", 
            "safety_issue": "Yes", 
            "time_frame": "-1.5,-1,-0.5,0.5,2,4,5,6,7,8,12,24 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862887"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "QT interval using individual heart rate correction", 
                "measure": "QTcI Interval", 
                "safety_issue": "Yes", 
                "time_frame": "-1.5,-1,-0.5,0.5,2,4,5,6,7,8,12,24 hours post-dose"
            }, 
            {
                "description": "AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,2,4,5,6,7,8,12,24 hours post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,2,4,5,6,7,8,12,24 hours post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,2,4,5,6,7,8,12,24 hours post-dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}